Inorganic Patents (Class 530/420)
-
Patent number: 6051694Abstract: Liquefied gases, compressed gases, and supercritical fluids are used to form protein particles without first dissolving the protein. The product material is expected to retain full activity and be devoid of residual processing chemicals such as solvents, salts, or surfactants.Type: GrantFiled: September 17, 1998Date of Patent: April 18, 2000Inventors: Trevor Percival Castor, Glenn Thomas Hong
-
Patent number: 6037457Abstract: The present invention provides methods of producing recombinant fibrinogen in a long-term mammalian cell culture system. Disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibrinogen in a serum-free medium for a time of at least one month at a level of at least 5 .mu.g/ml; and then collecting portions of the conditioned medium at least twice during the culturing time of at least one month, with each portion containing at least 5 .mu.g/ml of recombinant fibrinogen. Also disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibrinogen in a serum-free medium at a level greater than 1 .mu.g/ml; collecting at least a portion of the conditioned medium, and then purifying the fibrinogen from the medium by anion-exchange chromatography or affinity chromatography.Type: GrantFiled: January 31, 1997Date of Patent: March 14, 2000Assignee: The University of North Carolina at Chapel HillInventor: Susan T. Lord
-
Patent number: 6020313Abstract: The invention relates to a method for inducing bone formation via administration of an extract of devitalized, freeze dried Saos-2 cells. The extract is prepared by contacting the freeze dried Saos-2 cells, which are devitalized in the act of freeze drying, with a weak denaturing agent of the type used to separate proteins from cells. The extract does have properties superior to comparable treatment using whole Saos-2 cells. The extract is then further treated by applying it to a removing separating gel, and then fractions from the gel which have a molecular weight of from about 10 kd to about 60 kd. Also described are the extract itself, and formulations containing it.Type: GrantFiled: February 8, 1993Date of Patent: February 1, 2000Assignee: University of KansasInventors: H. Clarke Anderson, Howard H. T. Hsu
-
Patent number: 6013771Abstract: A process for providing an isoflavone rich protein isolate is provided, along with the isoflavone rich protein isolate produced thereby. A vegetable material containing protein and at least one isoflavone compound is extracted with an aqueous extractant having a pH above the isoelectric point of the protein, and preferably an alkaline pH. The protein and isoflavones are extracted into the extractant, and the extractant containing the protein and isoflavones is separated from insoluble vegetable protein materials to form a protein extract. The pH of the protein extract is adjusted to about the isoelectric point of the protein to precipitate the protein. The extract containing the precipitated protein is cooled to a temperature of about 40.degree. F. to about 80.degree. F., and then the protein is separated from the extract. Washing of the separated protein is avoided, or, is conducted with minimum amounts of water.Type: GrantFiled: June 9, 1998Date of Patent: January 11, 2000Assignee: Protein Technologies International, Inc.Inventors: Jerome L. Shen, Balagtas F. Guevara, Frank E. Spadafora, Barbara A. Bryan
-
Patent number: 6008197Abstract: The invention relates to a method for inducing bone formation via administration of an extract of devitalized, freeze dried Saos-2 cells. The extract is prepared by contacting the freeze dried Saos-2 cells, which are devitalized in the act of freeze drying, with a weak denaturing agent of the type used to separate proteins from cells. It is not clear that the active ingredient in the extract is a protein; however, the extract does have properties superior to comparable treatment using whole Saos-2 cells. Also, described are the extracts themselves and various compositions containing it.Type: GrantFiled: April 10, 1991Date of Patent: December 28, 1999Assignee: University of KansasInventor: H. Clarke Anderson
-
Patent number: 5994508Abstract: A process for providing an isoflavone rich protein isolate is provided, along with the isoflavone rich protein isolate produced thereby. A vegetable material containing protein and at least one isoflavone compound is extracted with an aqueous extractant having a neutral pH. The protein and isoflavones are extracted into the extractant, and the extractant containing the protein and isoflavones is separated from insoluble vegetable materials to form a protein extract. The pH of the protein extract is adjusted to about the isoelectric point of the protein to precipitate the protein. The extract containing the precipitated protein is cooled to a temperature of from about 40.degree. F. to about 80.degree. F., and then the protein is separated from the extract. The cool separation temperatures unexpectedly significantly increase the concentration of isoflavones recovered in the separated protein, while the neutral extract pH inhibits loss of protein normally observed at cool or cold separation temperatures.Type: GrantFiled: April 13, 1998Date of Patent: November 30, 1999Assignee: Protein Technologies International, Inc.Inventors: Barbara A. Bryan, Balagtas F. Guevara
-
Patent number: 5990289Abstract: The instant invention relate to a new method for the purification of proteins using copper chelate-affinity chromatography, wherein the impure or pre-purified protein is adsorbed on immobilized copper(II) ions, optionally washed with buffer and deionized water, washed with a solution of a Lewis-base, and finally eluted with deionized water.Type: GrantFiled: January 2, 1998Date of Patent: November 23, 1999Assignee: Novartis AGInventors: Pierre Fran.cedilla.ois Fauquex, Catherine Georges
-
Patent number: 5981715Abstract: The present invention is directed to a process for purifying alpha-1-PI. The process comprises providing an impure protein fraction which comprises alpha-1-PI. The impure protein fraction is suspended in an aqueous solution at pH 6. Insoluble proteins are recovered and resuspended in aqueous solution at pH 8.5. PEG is added to precipitate .alpha.-2 proteins. To the PEG supernatant precipitation, which comprises alpha-1-PI, is added ZnCl.sub.2 to precipitate crude alpha-1-PI. The crude alpha-1-PI is resolubilized and applied to an anion-exchange medium. A fraction comprising alpha-1-PI is recovered from the anion-exchange medium. Alpha-1-PI purified by the process has a specific activity about 1.0 units/OD.sub.280.Type: GrantFiled: March 31, 1997Date of Patent: November 9, 1999Assignee: Alpha Therapeutic CorporationInventors: Duk Sung Hwang, Evelyn Nario, Mark Lepe, Lyndon Luz, Hirokazu Ito, Kazuo Takechi
-
Patent number: 5977324Abstract: A method of concentrating a disease-related conformation of a protein such as the PrP.sup.Sc in a sample is disclosed. The method comprises liquefying the sample and adding a complexing agent such as phosphotungstic acid (PTA) which complexes preferentially or exclusively with the PrP.sup.Sc. After the complex is formed the composition is centrifuged until the complex settles at the bottom. Thereafter, the supernatant is poured away. The remaining pellet may be resuspended in an aqueous solution containing a protease inhibitor for storage. The PTA stains the PrP.sup.Sc making the resulting concentrated PrP.sup.Sc susceptible to further analysis, making it possible to quickly and efficiently determine the presence of PrP.sup.Sc and its concentration in a sample. The method can be used to render a sample non-infectious by removing all or substantial of the infectious form of a protein from a sample.Type: GrantFiled: February 20, 1998Date of Patent: November 2, 1999Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar
-
Patent number: 5912327Abstract: The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.Type: GrantFiled: March 20, 1997Date of Patent: June 15, 1999Assignee: Human Genome Sciences, Inc.Inventors: Yuling Li, Mark Oelkuct, Reiner L. Gentz
-
Patent number: 5900376Abstract: A method of a protein assay wherein a protein solution is treated with an acidic component followed by the addition of a precipitate-forming component, which results in precipitation of protein. The protein precipitate is collected and treated with one or more reagents of a protein assay to produce a characteristic protein color reaction. The concentration of protein is determined by measuring the optical density of protein color reaction and comparing the color reaction with a known standard.Type: GrantFiled: November 7, 1997Date of Patent: May 4, 1999Assignee: Geno Technology, Inc.Inventors: Manik Lal Das, Aftab Alam
-
Patent number: 5898067Abstract: A method of providing zinc containing crystals of a protein derivative which has a lysine residue which carries a lipophilic substituent on the .epsilon.-amino group, said method comprising providing a solution of the protein derivative in an alkaline buffer, which further contains a zinc salt, adjusting the pH value of the solution to a value between 7 and 10, and isolating the crystals formed.Type: GrantFiled: February 2, 1998Date of Patent: April 27, 1999Assignee: Novo Nordisk A/SInventors: Per Balschmidt, Jean Lesley Whittingham
-
Patent number: 5891429Abstract: A method for preparing and isolating a transformation vector containing CSF/cDNA is described. The method comprises:preparing RNA from a cell that produces CSF;preparing polyadenylated messenger RNA from said RNA;preparing single stranded cDNA from said messenger RNA;converting the single stranded cDNA to double stranded cDNA;inserting the double stranded cDNA into transformation vectors and transforming bacteria with said vector to form colonies;picking pools of 200 to 500 colonies each and isolating plasmid DNA from each pool;transfecting the plasmid DNA into suitable host cells for expressing CSF protein;culturing the transfected cells and assaying the supernatant for CSF activity; andselecting CSF positive pools and screening the colonies used to make the pool to identify a colony having CSF activity. Also described are a cDNA coding for a protein having CSF activity (i.e.Type: GrantFiled: June 6, 1995Date of Patent: April 6, 1999Assignee: The Novartis CorporationInventors: Steven C. Clark, Randal J. Kaufman, Gordon G. Wong, Elizabeth A. Wang
-
Patent number: 5880266Abstract: The invention relates to new protein derivatives of blood, blood-protein containing raw materials and hemoglobin, and more particularly to processed globin products, and to processes for producing these products. The processed globin products have an isoelectric point at a pH value below 5.5, an iron content of less than 1000 ppm, a ratio of His : Lys between 0.6 and 1.5, a Tyrosine content of at least 0.5% by weight, a Methionine content of at least 0.5% by weight, and a Lysine content of at least 5% by weight. The method for the production of the processed globin products according to the invention comprises treating the starting material at a pH above 12 and an the oxidizing treatment step the pH is kept below 12 while maintaining the temperature below 50.degree. C.Type: GrantFiled: March 21, 1997Date of Patent: March 9, 1999Assignee: Veos N.V.Inventor: Dirk R. De Buyser
-
Patent number: 5851792Abstract: An aglucone isoflavone enriched vegetable protein whey, whey protein material, high genistein material, high daidzein material, and aglucone isoflavone material are provided, as well as a process for producing the same from a vegetable protein whey. Isoflavone conjugates in a vegetable protein whey are converted to isoflavone glucosides by treating the whey at a temperature and a pH for a period of time sufficient to effect the conversion. The isoflavone glucosides are converted to aglucone isoflavones by enzymatic reaction to produce an aglucone isoflavone enriched vegetable protein whey. Aglucone isoflavone whey protein material is recovered from the aglucone isoflavone enriched vegetable protein whey. A high genistein content material, a high daidzein content material, and an aglucone isoflavone material are produced from an alcohol extract of the aglucone isoflavone whey protein material.Type: GrantFiled: April 3, 1996Date of Patent: December 22, 1998Inventors: Jerome Shen, Mark A. Roussey, Barbara A. Bryan, Maryann C. Allred
-
Patent number: 5846803Abstract: A process for the isolation and characterization of a gene enzyme system for the inactivation of the herbicide phenmedipham, wherein the enzyme is a carbamate hydrolase of Arthrobacter oxidans, which is responsible for the cleavage of the carbamate bond between the benzene rings of phenmedipham. This process includes the isolation of the carbamate hydrolase, the identification of the amino acid sequence of two BrCN cleavage peptides of the carbamate hydrolase, the synthesis of oligonucleotides for specific determination of the carbamate hydrolase sequence by hybridization and identification of the coding region, cloning and specifying the nucleotide sequence of the carbamate hydrolase gene from Arthrobacter oxidans.Type: GrantFiled: May 23, 1995Date of Patent: December 8, 1998Assignee: Hoechst Schering AgrEvo GmbHInventors: Hans-Dieter Pohlenz, Werner Boidol, Wolfgang Streber
-
Patent number: 5834427Abstract: The present invention relates to a purified casein phosphopeptide(CPP) having a novel amino acid sequence and a purified casein including same wherein the 25th Arg from N-terminal in a conventional CPP is replaced by Cys, rendering the CPPs to forming a dimer by disulfide bond. In the corresponding DNA sequence, cytosine is replaced by thymine to cause the amino acid replacement from Arginine(Arg) to Cysteine(Cys). The CPP or the casein containing same has an improved ability of solubilizing minerals and absorbing thereof in animals. The CPP or the beta-casein H containing same can be added to foodstuffs, beverages, medication, cosmetics, feed in an effective amount of enhancing a mineral absorption in animals. An oral composition comprising the beta-casein H or the inventive CPP and a pharmaceutically acceptable carrier can reduce or relieve a dentinal hypersensitivity.Type: GrantFiled: March 25, 1996Date of Patent: November 10, 1998Assignee: Sang Kee HanInventors: Sang Kee Han, Yoo Cheol Shin
-
Patent number: 5831022Abstract: A process for the production of essentially homogeneous soluble, stable, endotoxin free human recombinant interleukin-1.alpha. of enhanced specific activity is described. The process involves breaking transformed microbial cells containing expressed human interleukin-1.alpha. and separating the soluble supernatant from the insoluble cell components and then passing the supernatant through gel chromatography and ion-exchange chromatography steps.Type: GrantFiled: February 18, 1986Date of Patent: November 3, 1998Assignee: Hoffmann-La Roche Inc.Inventor: Alvin Seth Stern
-
Patent number: 5808006Abstract: A composition is provided comprising about 0.1 to 15 mg/ml of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: October 11, 1994Date of Patent: September 15, 1998Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5808008Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.Type: GrantFiled: March 12, 1997Date of Patent: September 15, 1998Assignee: Sloan-Kettering Institute of Cancer ResearchInventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
-
Patent number: 5780599Abstract: A method of producing chemically stable and biologically active growth hormone crystals and processes for production of pharmaceutical preparations containing these growth hormone crystals.Type: GrantFiled: December 7, 1994Date of Patent: July 14, 1998Assignee: Novo Nordisk A/SInventors: Flemming Junker, Claus Friss Theisen
-
Patent number: 5773588Abstract: There is provided a method for purifying a refold somatotropin monomer from a mixture of somatotropin monomers and somatotropin oligomers in an aqueous solution having a urea concentration of greater than 3 molar by the addition of an acid to reduce the pH of the solution to below about 7.7 to selectively precipitate the oligomers in the most part.Type: GrantFiled: December 4, 1995Date of Patent: June 30, 1998Assignee: Monsanto CompanyInventors: Dennis C. Owsley, Suvit Kulvaranon
-
Patent number: 5763389Abstract: Aglucone isoflavone enriched vegetable protein extract and isolate and processes for producing and recovering are disclosed. The aglucone isoflavone extract is made by extracting a vegetable protein material comprising glucone isoflavones with an aqueous extractant having a pH above about the isoelectric point of the protein material to produce an aqueous extract, and reacting the glucone isoflavones with a sufficient amount of beta-glucosidase enzyme or esterase enzyme for a time period, temperature, and pH sufficient to convert at least a majority of the glucone isoflavones in the extract to aglucone isoflavones and thereby produce the aglucone isoflavone enriched extract. The aglucone isoflavone enriched isolates are produced by adjusting the pH of the reacted extract to about the isoelectric point of the vegetable protein material to precipitate the protein material, and separating the protein material to produce an aglucone enriched protein isolate.Type: GrantFiled: April 12, 1996Date of Patent: June 9, 1998Assignee: Protein Technologies International, Inc.Inventors: Jerome L. Shen, Barbara A. Bryan
-
Patent number: 5756672Abstract: A composition is provided comprising about 0.1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: June 6, 1995Date of Patent: May 26, 1998Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5679776Abstract: The invention relates to a process for preparing a concentrate of Factor VIII-von Willebrand factor complex having high specific activity from total (non-cryoprecipitated) plasma.The process comprises pre-purifying by means of a double treatment with barium chloride and with aluminium hydroxide.The process then comprises purification by chromatography on an anion exchange resin, of the DEAE-Fractogel type.The process includes a step of viral inactivation by means of a treatment with solvent-detergent.The process also makes it possible to recover fibrinogen, albumin, immunoglobulins, antithrombin III, fibronectin and prothrombin complex, from the same plasma.The different concentrates obtained using the process according to the invention are intended, in particular, for therapeutic use.Type: GrantFiled: September 5, 1990Date of Patent: October 21, 1997Assignee: Centre Regional de Transfusion Sanguine de LilleInventors: Miryana Burnouf-Radosevich, Thierry Burnouf
-
Patent number: 5663304Abstract: A composition is provided comprising about 0.1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: August 20, 1993Date of Patent: September 2, 1997Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5637561Abstract: Aglucone isoflavone enriched vegetable protein whey, whey protein and processes for producing and recovering such are disclosed. Aglucone isoflavone enriched vegetable protein whey is made by treating whey comprising glucone isoflavones with a sufficient amount of beta-glucosidase enzyme or esterase enzyme or acid to convert at least a majority of the glucone isoflavones to aglucones and thereby provide an aglucone enriched whey. An aglucone enriched whey protein is obtained by recovery of the protein.Type: GrantFiled: April 12, 1996Date of Patent: June 10, 1997Assignee: Protein Technologies International, Inc.Inventors: Jerome L. Shen, Barbara A. Bryan
-
Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
Patent number: 5623059Abstract: A process for the microbial production of a protein susceptible to inactivation in a fluid production medium by continuously and reversibly protecting said protein against said inactivation during the production stage, separating the protein from the production medium, deprotecting the protein, and recovering the protein product. The process is especially useful for obtaining substantially increased yields of the protein in question by continuously precipitating said protein.Type: GrantFiled: August 16, 1994Date of Patent: April 22, 1997Assignee: Novo Nordisk A/SInventors: Per L. Joergensen, Poul E. Pedersen, Joergen Petersen, Torben K. Nielsen, Jan M. Mikkelsen -
Patent number: 5616328Abstract: There is provided by this invention a novel method of preparing Gram-negative bacterial vaccines. The method comprises providing a concentrated Gram-negative bacterial antigenic preparation,adsorbing the preparation with a mineral carrier capable of binding free-endotoxin in the antigenic preparation in an amount effective to produce optimal binding of endotoxin and antigen and diluting the adsorbed preparation for use in a vaccine. Also provided by this invention is a vaccine produced by the method of this invention. Also provided by this invention is a Gram-negative bacterial vaccine wherein the improvement comprises a concentration of mineral carrier in the vaccine which is less than 5.0% v/v. Also provided by this invention is a Gram-negative bacterial vaccine comprising a mineral carrier wherein the amount of the mineral carrier in the vaccine has been predetermined by the method of this invention.Type: GrantFiled: July 11, 1994Date of Patent: April 1, 1997Assignee: Pfizer Inc.Inventors: David S. Roberts, Donald A. Dearwester, Leroy A. Swearingin
-
Patent number: 5610277Abstract: An improved alcohol-free method for fractionating gluten into gliadin and glutenin fractions is provided where an acidic dispersion of gluten is formed with a reducing agent (e.g., sodium metabisulfite) operable for breaking disulfide bonds in the gluten protein. Thereafter, the pH of the dispersion is raised to cause glutenin to precipitate while leaving gliadin suspended in the dispersion. The respective fractions can then be separated by decanting or centrifugation. In preferred processing, the dispersion is reacidified prior to separation in order to achieve a higher degree of separation of the glutenin and gliadin.Type: GrantFiled: September 11, 1995Date of Patent: March 11, 1997Assignee: Midwest Grain ProductsInventors: Sukh Bassi, Clodualdo C. Maningat, Rangaswamy Chinnaswamy, Darren R. Gray, Li Nie
-
Patent number: 5525472Abstract: Applicants describe methods for purifying human ApoE or analog thereof from recombinant bacterial cells with minimal protein aggregation and degradation during the purification process. The invention involves the addition of neutralized fatty acids to the medium during cell disruption and the use of a non-ionic detergent during the purification process. Additionally applicants describe a method for increasing the production of ApoE or analog thereof in a bacterial host by adding to the culture medium neutralized fatty acids, fatty acid precursors, triglycerides, triglyceride precursors or acetate. Pharmaceutical and diagnostic uses of the ApoE analog are described.Type: GrantFiled: November 3, 1994Date of Patent: June 11, 1996Assignee: Bio-Technology General Corp.Inventors: Ruth Lifshitz, Meir Fischer, Benjamin Greenman, Daniel Bartfeld
-
Patent number: 5523215Abstract: A method for isolating a desired protein which comprises: providing a host cell expressing the desired protein as an insoluble aggregate; culturing the host cell with an effective mount of Cu.sup.++ ; disrupting the host cell producing a lysate; incubating the insoluble fraction non-disulfide-bond reducing or non-copper competing chaotropic conditions to solubilize contaminants; separating the insoluble from the soluble fraction; and exposing the insoluble fraction to disulfide-bond reducing or copper competing chaotropic conditions to solubilize the desired protein.Type: GrantFiled: April 16, 1992Date of Patent: June 4, 1996Assignee: Chiron CorporationInventors: Lawrence S. Cousens, Patricia Tekamp-Olson
-
Patent number: 5521287Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. The thus obtained human serum albumin can further be purified by treating recombinant human serum albumin with a hydrophobic chromatography carrier at pH of 2 to 5 and a salt concentration of 0.4 to 1 and exposing the carrier to a pH of 6 to 8 and a salt concentration of 0.01 to 0.Type: GrantFiled: February 25, 1994Date of Patent: May 28, 1996Assignee: The Green Cross CorporationInventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Furuhata, Kazuya Takeshima, Kaeko Kamide, Munehiro Noda, Masahide Kondo, Syoichi Ishikawa, Kazuhiro Oohara, Kazumasa Yokoyama, Nagatoshi Fujiwara
-
Patent number: 5482924Abstract: The invention relates to proteinaceous compositions capable of modulating the development of erythroid progenitors such as obtainable from a biological material selected from bone marrow culture supernatants, or kidney cell lysates by contacting said biological material with a specific ligand for the proteinaceous compositions, desorbing said proteinaceous compositions and recovering same by elution. Said compositions are useful in therapeutics.Type: GrantFiled: December 9, 1992Date of Patent: January 9, 1996Assignee: Centre National de La RechercheInventors: Julien Royet, Sylvie Arnaud, Guy Mouchiroud, Jean P. Blanchet
-
Patent number: 5462863Abstract: A method for recovering hepatitis B surface antigen protein from transformed yeast cells including the steps of (i) obtaining an aqueous homogenate of the yeast cells; (ii) enriching the hepatitis B surface antigen protein in the homogenate with a protein-aggregating reagent to form a precipitate which contains hepatitis B surface antigen protein; (iii) dissolving the precipitate in a buffer to form a suspension; and (iv) post-homogenizing the suspension to obtain a 10% to 50% increase in yield of the hepatitis B surface antigen protein as calculated based on a yield achieved without performing the post-homogenizing step.Type: GrantFiled: April 28, 1994Date of Patent: October 31, 1995Assignee: Development Center for BiotechnologyInventors: Jih-Han Hsieh, Shu-Ching Shih, Wei-Kuang Chi, Yi-Ding Chu, Ae-Ning Lin
-
Patent number: 5441734Abstract: The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.Type: GrantFiled: February 25, 1993Date of Patent: August 15, 1995Assignee: Schering CorporationInventors: Paul Reichert, Charles McNemar, Nagamani Nagabhushan, Tattanahalli L. Nagabhushan, Stephen Tindall, Alan Hruza
-
Patent number: 5437986Abstract: An insoluble mammalian protein is extracted from transformed bacteria expressing the mammalian protein while avoiding irreversible insolubilization of bacterial host proteins by homogenizing the fermentation broth, centrifuging the homogenized broth and removing the supernatant liquid for the inclusion body containing pellet. In another embodiment, the pH of the homogenized broth is adjusted to 2.0 prior to centrifugation. The acidified broth is then centrifuged, and the pellet is resuspended in buffer, homogenized again, and the inclusion body is isolated by centrifugation.Type: GrantFiled: June 22, 1994Date of Patent: August 1, 1995Assignee: Schering CorporationInventors: Yair Alroy, Jingdong Zhu, Russell Condon
-
Patent number: 5432265Abstract: The continuous removal of solid products from a high-pressure system is achieved by operating a high-pressure pump in reverse to gradually reduce pressure at the exit line to atmospheric pressure. This process allows solid products to exit the system while at the same time maintaining high pressure in the reactor.Type: GrantFiled: July 27, 1993Date of Patent: July 11, 1995Assignee: The United States of America as represented by the Secretary of AgricultureInventor: Peggy M. Tomasula
-
Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
Patent number: 5371198Abstract: A process for the microbial production of a protein susceptible to inactivation in a fluid production medium by continuously and reversibly protecting said protein against said inactivation during the production stage, separating the protein from the production medium, deprotecting the protein, and recovering the protein product. The process is especially useful for obtaining substantially increased yields of the protein in question by continuously precipitating said protein.Type: GrantFiled: March 9, 1992Date of Patent: December 6, 1994Assignee: Novo Nordisk A/SInventors: Per L. Joergensen, Poul E. Pedersen, Joergen Petersen, Torben K. Nielsen, Jan. M. Mikkelsen -
Patent number: 5371195Abstract: In the method for purifying factor VIII from cryoprecipitate, which is dissolved and then treated with alumina gel, the extract is diluted to a protein concentration not exceeding approximately 5 g/l and subjected to viral inactivation with solvent/detergent, the inactivated extract containing the solvent/detergent is then subjected to chromatography on a weak anion exchange column which is hydrophilic in nature and factor VIII is then eluted with a dissociating buffer.Type: GrantFiled: September 23, 1992Date of Patent: December 6, 1994Assignee: Pasteur MerieuxInventors: Michel Grandgeorge, Charles Lutsch
-
Patent number: 5332803Abstract: A process for the preparation of an amylase inhibitor is disclosed which comprises the steps of:(a) extracting wheat, wheat flour or wheat gluten with water, a dilute acid, a dilute alkali or an aqueous alcohol to produce a solution containing the amylase inhibitor;(b) adding a polysaccharide to said solution to form an insoluble complex of the amylase inhibitor with the polysaccharide and separating the insoluble complex from the solution;(c) dissolving or dispersing said complex in a solution, then separating the polysaccharide from the solution to collect a solution containing the amylase inhibitor; and(d) treating the collected solution with a cation exchanger to recover the amylase inhibitor from fractions that have not been adsorbed on the cation exchanger.Type: GrantFiled: April 19, 1993Date of Patent: July 26, 1994Assignees: Nisshin Flour Milling Co., Ltd., Nagata Sangyo Co. Ltd.Inventors: Toshiyuki Miyazaki, Ryuji Murayama, Toshihisa Morimoto
-
Patent number: 5304637Abstract: Methods are provided for improved production of hIL-3 either in glycosylated form from mammalian and yeast cells or in unglycosylated form from prokaryotes. Recombinantly produced human IL-3 is purified in a series of steps, initially employing hydrophobic interaction, followed by ion exchange chromatography and gel filtration.Type: GrantFiled: March 13, 1990Date of Patent: April 19, 1994Assignee: Gist-brocades N.V.Inventors: Lambertus C. J. Dorssers, Gerard Wagemaker, Yvonne J. Vos, Robert W. Van Leen, Maria L. N. Persoon
-
Patent number: 5300632Abstract: The present invention provides a method for purification of a surface exposed, immunogenic outer membrane protein of Haemophilus influenzas which is conserved amongst strains. The protein, designated P6, is relatively free of detergent, contaminating RNA and undesirable cellular components.In accordance with the present invention, there is provided a method for purifying an immunogenic outer membrane protein of H. influenzas consisting essentially of:a) suspending H.Type: GrantFiled: December 12, 1991Date of Patent: April 5, 1994Assignee: Research Foundation of State University of New YorkInventors: Timothy F. Murphy, Michael A. Apicella
-
Patent number: 5288856Abstract: A method of isolating cystine rich acid-stable, biologically active proteins comprising the steps of co-precipitation by acidification of said proteins together with at least one acid-sensitive protein; isolation of said proteins from the co-precipitate by its resuspension in aqueous solution and the subsequent recovery of the proteins from the supernatant.Type: GrantFiled: March 19, 1992Date of Patent: February 22, 1994Inventor: Pierre Amiguet
-
Patent number: 5288853Abstract: There is provided in accordance with the practice of this invention a process for separating Factor VIII complex from an impure protein fraction containing Factor VIII complex. An aqueous solution of the impure protein fraction containing Factor VIII complex is applied to a heparin-coupled chromatographic medium, to bind the Factor VIII complex to the medium. The Factor VIII is then recovered from the heparin-coupled chromatographic medium by elution with an aqueous solution comprising CaCl.sub.2 and histidine. The recovered Factor VIII is further purified by precipitation with a solution comprising glycine and NaCl, and washing the resultant precipitate with a solution comprising histidine, glycine, and NaCl to provide a Factor VIII complex solution with a specific activity of about 70 to about 150 units/mg.Type: GrantFiled: April 30, 1992Date of Patent: February 22, 1994Assignee: Alpha Therapeutic CorporationInventors: Prabir Bhattacharva, Toshiharu Motokubota
-
Patent number: 5286716Abstract: Protein which acts as an inhibitor of the proliferation of endothelial ce which is obtainable from baby hamster kidney cells (ATCC CCL 10) and has a molecular weight between 60 and 100 kD in gel filtration under native conditions and is thermally stable at 60.degree. C., as well as a process for its isolation and its use in the treatment of diseases.Type: GrantFiled: August 25, 1992Date of Patent: February 15, 1994Assignee: Max Planck Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Werner Risau, Hannes Drexler
-
Patent number: 5286849Abstract: The present invention relates to a process for purifying Factor IX from an impure protein fraction containing Factor IX. The purification process comprises the steps of adding a solvent and a detergent to an impure protein fraction and incubating the solvent/detergent protein solution to inactivate any viral contaminants. Factor IX is purified from the solvent/detergent protein solution by chromatography on a sulfated polysaccharide resin without first removing the solvent and detergent prior to the purification on the sulfated polysaccharide resin. The Factor IX, purified by the process has a specific activity of at least 85 units/mg.Type: GrantFiled: July 14, 1992Date of Patent: February 15, 1994Assignee: Alpha Therapeutic CorporationInventor: Steven W. Herring
-
Patent number: 5276141Abstract: The invention proposes a process for purifying a highly glycosylated protein from a crude preparation which comprises the action (i) of adding to said preparation a divalent metal ion in a sufficient amount in order to form a mixture which precipitates and (ii) after precipitation, of harvesting said protein from the mixture supernatant.Type: GrantFiled: February 14, 1992Date of Patent: January 4, 1994Assignee: Transgene S.A.Inventor: Hanno Kolbe
-
Patent number: 5258177Abstract: A method of preparing an IgA rich preparation comprising exposing a plasma fraction to an amino acid, organic salt or inorganic salt with optional chromatographic treatment yielding a product suitable for use in medical conditions treatable with IgA.Type: GrantFiled: December 10, 1991Date of Patent: November 2, 1993Assignee: Alpha Therapeutic CorporationInventors: Yahiro Uemura, Sunnie Park, Raja R. Mamidi, Charles M. Heldebrandt
-
Patent number: RE35747Abstract: A biochemical procedure for identification and characterization of cells in a biopsy or sample of a body fluid. The method can be used to determine cell type, i.e. epidermal, neuronal; tissue of origin, i.e. breast tissue, liver tissue; and degree of abnormality. The procedure can also be used to make antibodies and hybridization probes to detect cell or tissue specific antigens and nuclear matrix associated nucleic acids in cellular material and body fluids.The procedure is based on the isolation and analysis of the components of a specific subcellular protein fraction referred to here as the "nuclear matrix". The nuclear matrix includes proteins and nuclear matrix associated DNA specific to different cell types. These proteins and nucleic acids are altered or new ones expressed as a result of viral infection, genetic defects or malignancy.Type: GrantFiled: November 19, 1991Date of Patent: March 17, 1998Assignee: Massachusetts Institute of TechnologyInventors: Sheldon Penman, Edward G. Fey